American Vanguard (AVD) Q1 2025 earnings summary

Executive summary

• Q1 2025 net sales declined 14% year-over-year to $115.8 million, with both domestic and international sales down due to customer destocking, discontinued herbicide, and weak market demand.

• Adjusted EBITDA dropped to $3.0 million from $15.5 million, and net loss was $8.5 million (EPS $(0.30)), compared to net income of $1.6 million (EPS $0.06) in Q1 2024.

• Operating expenses were reduced by $5 million year-over-year, with significant cuts in R&D and SG&A, and net working capital improved by $85–$86 million.

• Channel inventories in the U.S. reached historic lows, with destocking continuing through April but signs of replenishment emerging in May and June.

• The company completed delayed 10-K and 10-Q filings, with only minor changes from previously released unaudited results; material weaknesses in internal controls identified, especially in the Australian subsidiary.

Financial highlights

• Net sales for Q1 2025 were $115.8 million, down from $135.1 million in Q1 2024; international sales comprised 37% of total revenue.

• Adjusted EBITDA was $3.0 million, compared to $15.5 million a year ago, with margin dropping to 2.6% from 11.3%.

• Gross profit fell 29% to $30.2 million, with gross margin down to 26% from 31% last year.

• Operating loss was $4.3 million versus operating income of $6.1 million last year.

• Net loss was $8.5 million versus net income of $1.6 million; EPS $(0.30) vs. $0.06.

Outlook and guidance

• Full-year 2025 adjusted EBITDA guidance lowered to $40–$44 million (from $45–$52 million); revenue guidance set at $535–$545 million.

• CapEx for 2025 expected to be $8–$9 million, with most free cash flow allocated to debt paydown.

• Management expects industry conditions and demand to improve in the second half of 2025, with margin enhancement targeted for 2026 and beyond.

• Further cost reduction initiatives are planned if market conditions do not improve.

• Long-term goal remains a 15% adjusted EBITDA margin through the cycle.